<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/EC23DA53-CA73-4104-A3F6-2A9523484E69"><gtr:id>EC23DA53-CA73-4104-A3F6-2A9523484E69</gtr:id><gtr:name>Queen's University of Belfast</gtr:name><gtr:department>Sch of Pharmacy</gtr:department><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Belfast</gtr:line4><gtr:line5>County Antrim</gtr:line5><gtr:postCode>BT7 1NN</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EC23DA53-CA73-4104-A3F6-2A9523484E69"><gtr:id>EC23DA53-CA73-4104-A3F6-2A9523484E69</gtr:id><gtr:name>Queen's University of Belfast</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Belfast</gtr:line4><gtr:line5>County Antrim</gtr:line5><gtr:postCode>BT7 1NN</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:line4>Swindon</gtr:line4><gtr:line5>Wiltshire</gtr:line5><gtr:postCode>SN2 1ET</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>CO_FUNDER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/AF82F35A-7B02-402E-B41C-D30667FD003C"><gtr:id>AF82F35A-7B02-402E-B41C-D30667FD003C</gtr:id><gtr:firstName>Ryan</gtr:firstName><gtr:surname>Donnelly</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FE020534%2F1"><gtr:id>7DD0DCFD-8A9D-4F8F-8928-7E3461BD800E</gtr:id><gtr:title>Transdermal delivery of macromolecules mediated by microneedle arrays</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/E020534/1</gtr:grantReference><gtr:abstractText>Traditional pharmaceutical drugs are small chemical molecules that treat the symptoms of a disease. Biopharmaceuticals are large biological molecules, known as peptides and proteins and these target the underlying mechanisms and pathways of a disease. They can deal with targets in humans that are not accessible with traditional medicines. Recently, there have been rapid and revolutionary developments in this field of biotechnology. Therapeutic peptides and proteins are expected to be used extensively in coming years as vaccines and treatments for cancer, high blood pressure, pain and blood clots, as well as many other illnesses. However, one of the major challenges to successful clinical use of these 'biotech' molecules is their efficient delivery to the site of action. The body breaks these drugs down when they are swallowed and they are generally not well-absorbed into the blood. As a result, they have to be given frequently by injection, which causes pain and means that such drugs are usually only given to people in hospital. If these new drugs could be delivered across the skin, then many of the problems associated with their administration could be overcome. However, in order to do this, it is necessary to overcome the barrier presented by the outer layer of the skin. This skin layer, known as the stratum corneum, has evolved to protect us from the external environment. It prevents entry of dirt and microorganisms, but also most medicines. In this project, a novel type of transdermal patch will be developed that will by-pass the stratum corneum barrier. On its surface will be many tiny needles that pierce the stratum corneum without causing any pain - the sensation is said to feel like a cat's tongue or sharkskin. These needles will either dissolve quickly, leaving tiny holes in the stratum corneum, which will let proteins and peptides enter the body, or swell, turning into a jelly-like material that keeps the holes open and will allow continuous drug delivery. The technology developed here is unique and could potentially revolutionise delivery of peptides and proteins. This is likely to be of great benefit to patients, as it will make these advanced medicines readily available to everybody.</gtr:abstractText><gtr:technicalSummary>Advances in biotechnology have allowed the economical and large-scale production of therapeutically important peptides and proteins. One of the major challenges to successful clinical use of these 'biotech' molecules is their efficient delivery to the site of action. Due to enzymatic breakdown and poor absorption, parenteral delivery is presently the most routinely-employed method for administering macromolecular agents. Transdermal delivery offers one potential means of overcoming many of the problems associated with delivery of these drugs. Microneedle arrays are minimally invasive devices that can by-pass the stratum corneum barrier to drug diffusion. Such microneedle arrays are applied to the skin surface and painlessly pierce the epidermis, creating microscopic holes through which drugs diffuse. In this project, it is intended to develop a unique transdermal drug delivery system based on microneedle arrays. Following thorough physicochemical characterisation of candidate materials and microneedle geometries, the device will be produced and used to deliver model macromolecules across the skin.</gtr:technicalSummary><gtr:fund><gtr:end>2010-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2007-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>338839</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Pharmacists in Schools</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>9B8B7FA1-1BAB-4FEE-BB58-6B332DF32B20</gtr:id><gtr:impact>Over 100 workshops held in schools in N. Ireland.

This led to further fudning from RCUK in the SUPI initiative and our participation at BBSRC's Great British Bioscience Festival

High interest in our work and consistent application numbers to study pharmacy at QUB</gtr:impact><gtr:outcomeId>544a620fdec761.14926242</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://www.qub.ac.uk/directorates/degreeplus/RoutestoDegreePlus/RouteB/PharmacistsinSchools/</gtr:url><gtr:year>2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>32387</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>In vivo evaluation of microneedle arrays</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>Reckitt Benckiser</gtr:fundingOrg><gtr:id>2CE6DBB3-BB09-4856-A1D5-61C19B18AA0C</gtr:id><gtr:outcomeId>5ec88f7c5ec88f90</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2013-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>58804</gtr:amountPounds><gtr:country>France, French Republic</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Physical characterisation of microneedle arrays for cosmaceutical delivery</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>L'Oreal (Paris)</gtr:fundingOrg><gtr:id>18186889-683D-4202-B12E-8E7D814E4A5A</gtr:id><gtr:outcomeId>r-1649931652.1453967068805c2</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2013-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>140441</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Microneedle arrays for transdermal delivery</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>Reckitt Benckiser</gtr:fundingOrg><gtr:id>D772E0EC-2945-4559-8292-E9C737AA7BC9</gtr:id><gtr:outcomeId>r-2383188588.901598506a3238e</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>92567</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Polymeric Microprojection Arrays for Transdermal Delivery of Active Pharmaceutical Ingredients.</gtr:description><gtr:end>2010-03-02</gtr:end><gtr:fundingOrg>Invest Northern Ireland</gtr:fundingOrg><gtr:fundingRef>PoC21A</gtr:fundingRef><gtr:id>CFBDA57E-3FE0-4850-BB8E-8EA04CD446F8</gtr:id><gtr:outcomeId>5ec8d6bc5ec8d6d0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2009-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>92567</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Polymeric Microprojection Arrays for Transdermal Delivery of Active Pharmaceutical Ingredients.</gtr:description><gtr:end>2010-02-02</gtr:end><gtr:fundingOrg>Invest Northern Ireland</gtr:fundingOrg><gtr:fundingRef>PoC21A</gtr:fundingRef><gtr:id>CBBD123C-BCAC-4B43-89DD-66FCE48FB0EB</gtr:id><gtr:outcomeId>r-7212101916.98009406a38db0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2009-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>94154</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Microneedle-enhanced neonatal therapeutic drug monitoring</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>Action Medical Research</gtr:fundingOrg><gtr:fundingRef>GN2024</gtr:fundingRef><gtr:id>EFA03F49-C752-470D-89DC-4DB877673EBC</gtr:id><gtr:outcomeId>5ec209865ec20990</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>32387</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>In vivo evaluation of microneedle arrays</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>Reckitt Benckiser</gtr:fundingOrg><gtr:id>57BCFBA0-CF2A-42E0-BDA0-FF33A1C75764</gtr:id><gtr:outcomeId>r-6038143957.06927806a322b2</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2013-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>327441</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Microneedle-mediated enhanced Raman therapeutic drug monitoring</gtr:description><gtr:end>2014-03-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>EP/H021647/1</gtr:fundingRef><gtr:id>02D4AE2F-E0CD-4DA0-A7D5-A5CBB98B66B0</gtr:id><gtr:outcomeId>5ed964b45ed964c8</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>94154</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Microneedle-enhanced neonatal therapeutic drug monitoring</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>Action Medical Research</gtr:fundingOrg><gtr:fundingRef>GN2024</gtr:fundingRef><gtr:id>A051C344-5CFE-4CD3-A9A3-F3F8833A8DEB</gtr:id><gtr:outcomeId>r-8575350491.865864068be278</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>58804</gtr:amountPounds><gtr:country>France, French Republic</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Physical characterisation of microneedle arrays for cosmaceutical delivery</gtr:description><gtr:end>2014-10-02</gtr:end><gtr:fundingOrg>L'Oreal (Paris)</gtr:fundingOrg><gtr:id>45C2A118-A367-421A-AE5F-90429F757068</gtr:id><gtr:outcomeId>5ebe20465ebe205a</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>72401</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Design and characterisation of novel microneedle arrays for delivery of gene-based vaccines.</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>Touchlight Genetics Ltd</gtr:fundingOrg><gtr:id>5026AA48-ACB8-46AE-8AEA-D00341B0141B</gtr:id><gtr:outcomeId>5ebe2ca85ebe2cbc</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2013-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>709446</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Manufacture and applicator technologies for commercialisation of polymeric microneedle arrays</gtr:description><gtr:end>2015-08-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BB/K020234/1</gtr:fundingRef><gtr:id>A2123CF2-2523-4D90-9DF1-622316F74260</gtr:id><gtr:outcomeId>5ee5a0625ee5a076</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>140441</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Microneedle arrays for transdermal delivery</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>Reckitt Benckiser</gtr:fundingOrg><gtr:id>9EDA7789-33E9-4CC3-A091-D510883BF167</gtr:id><gtr:outcomeId>5ec8903a5ec89044</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>97070</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>The use of a novel technology platform to create a DNA vaccine for prostate cancer</gtr:description><gtr:end>2016-12-02</gtr:end><gtr:fundingOrg>Prostate Cancer UK</gtr:fundingOrg><gtr:fundingRef>S12-006</gtr:fundingRef><gtr:id>DA14EAC7-90A2-4CBB-9A34-DBEFE6BF3B8C</gtr:id><gtr:outcomeId>r-5577991051.206357068f1d76</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50168</gtr:amountPounds><gtr:country>Germany, Federal Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Design and characterisation of microneedle arrays for delivery of active cosmaceutical ingredients.</gtr:description><gtr:end>2012-07-02</gtr:end><gtr:fundingOrg>Beiersdorf AG</gtr:fundingOrg><gtr:id>05D5700C-F906-4F09-8CF9-AFF096D23546</gtr:id><gtr:outcomeId>r-228274455.506610180688127e</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2011-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50168</gtr:amountPounds><gtr:country>Germany, Federal Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Design and characterisation of microneedle arrays for delivery of active cosmaceutical ingredients.</gtr:description><gtr:end>2012-05-02</gtr:end><gtr:fundingOrg>Beiersdorf AG</gtr:fundingOrg><gtr:id>A2B13AF8-E102-4474-A08F-0F5F512098D0</gtr:id><gtr:outcomeId>5ebe26725ebe2686</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2011-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>97070</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>The use of a novel technology platform to create a DNA vaccine for prostate cancer</gtr:description><gtr:end>2016-12-02</gtr:end><gtr:fundingOrg>Prostate Cancer UK</gtr:fundingOrg><gtr:fundingRef>S12-006</gtr:fundingRef><gtr:id>088FD93E-42E2-4F1C-9833-8FCC48E9CF3E</gtr:id><gtr:outcomeId>5ec49ec65ec49eda</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>95345</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>In vitro and in vivo safety investigations to support the commercialisation of novel microneedle arrays for transdermal drug delivery</gtr:description><gtr:end>2011-07-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BB/FOF/287</gtr:fundingRef><gtr:id>57B3D4F5-47EF-422B-82E2-2B9745F2A52B</gtr:id><gtr:outcomeId>5ee48dee5ee48e0c</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2010-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>11600</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Industrial scale microneedle design and manufacture and microneedle applicator design</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BB/FOF/PF/3/12</gtr:fundingRef><gtr:id>526BFB5D-2F4E-487F-A182-491932A55111</gtr:id><gtr:outcomeId>5ee493665ee4937a</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>142000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Optical coherence tomographic characterisation of drug delivery systems and biomaterials</gtr:description><gtr:end>2016-05-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>WT094085MA</gtr:fundingRef><gtr:id>CBC0AA87-9EDD-40FA-9EBB-6B2527E58492</gtr:id><gtr:outcomeId>5ee19f3a5ee19f4e</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-06-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>Working with a range of international companies to develop commercial products. More than &amp;pound;2 million in additional funding has be obtained based on the findings of this grant.

This technology has great potential economic and societal value</gtr:description><gtr:firstYearOfImpact>2009</gtr:firstYearOfImpact><gtr:id>2F45C384-BE16-4FB9-BACD-74E62CADFB1F</gtr:id><gtr:impactTypes><gtr:impactType>Societal,Economic</gtr:impactType></gtr:impactTypes><gtr:outcomeId>544a5d7b1b4181.76725799</gtr:outcomeId><gtr:sector>Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>Discovery and development of hydrogel-forming microneedle arrays that have capabilities in delivery of biomolecules, high dose small molecules and capture of skin interstitial fluid for minimally-invasive monitoring/diagnosis</gtr:description><gtr:exploitationPathways>Working with many international companies to commercialise</gtr:exploitationPathways><gtr:id>7DC5E4E6-290D-4877-AD39-5ADD6F77433F</gtr:id><gtr:outcomeId>r-4995578746.3072497782445e</gtr:outcomeId><gtr:sectors><gtr:sector>Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors><gtr:url>http://pure.qub.ac.uk/portal/en/persons/ryan-donnelly(7f46a524-c3a4-46a9-b347-834f0a3640f2).html</gtr:url></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>FE8C0E39-BF42-46B9-9CC7-51C69B0A19E2</gtr:id><gtr:title>Influence of array interspacing on the force required for successful microneedle skin penetration: theoretical and practical approaches.</gtr:title><gtr:parentPublicationTitle>Journal of pharmaceutical sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4e3e10400e724c22fef6b45c03ccf27b"><gtr:id>4e3e10400e724c22fef6b45c03ccf27b</gtr:id><gtr:otherNames>Olatunji O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-3549</gtr:issn><gtr:outcomeId>544a5e92acf0c6.07194312</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BF1D8A64-72EA-42A7-AE84-217D01174A11</gtr:id><gtr:title>Design and physicochemical characterisation of novel dissolving polymeric microneedle arrays for transdermal delivery of high dose, low molecular weight drugs.</gtr:title><gtr:parentPublicationTitle>Journal of controlled release : official journal of the Controlled Release Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a5b7048b696adf8904e091eaf21f562b"><gtr:id>a5b7048b696adf8904e091eaf21f562b</gtr:id><gtr:otherNames>McCrudden MT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0168-3659</gtr:issn><gtr:outcomeId>doi_55f94a94ac9ca7e3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>08900061-F5F6-4511-A74E-A8A7BAC3A369</gtr:id><gtr:title>Effect of microneedle treatment on the skin permeation of a nanoencapsulated dye.</gtr:title><gtr:parentPublicationTitle>The Journal of pharmacy and pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/30e85c1552618e805df26dff11084b6a"><gtr:id>30e85c1552618e805df26dff11084b6a</gtr:id><gtr:otherNames>Gomaa YA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-3573</gtr:issn><gtr:outcomeId>544a5e92dea4f1.91115093</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2B37251B-4969-44F3-856C-58650879AA8C</gtr:id><gtr:title>Dissolving polymeric microneedle arrays for electrically assisted transdermal drug delivery.</gtr:title><gtr:parentPublicationTitle>Journal of controlled release : official journal of the Controlled Release Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/77a908b607119e89548057df19eb3ddc"><gtr:id>77a908b607119e89548057df19eb3ddc</gtr:id><gtr:otherNames>Garland MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0168-3659</gtr:issn><gtr:outcomeId>544a5e944e3ce8.01746340</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3EBB4434-C4FC-4D51-B439-B0E298E5D027</gtr:id><gtr:title>Hydrogel-Forming Microneedle Arrays Made from Light-Responsive Materials for On-Demand Transdermal Drug Delivery.</gtr:title><gtr:parentPublicationTitle>Molecular pharmaceutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ef02abd7a5e4719b50c5d9bf4f8a28db"><gtr:id>ef02abd7a5e4719b50c5d9bf4f8a28db</gtr:id><gtr:otherNames>Hardy JG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1543-8384</gtr:issn><gtr:outcomeId>585d7249680be5.01626930</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C3375414-023F-4137-B43C-C1E64C78230A</gtr:id><gtr:title>Laser-engineered dissolving microneedles for active transdermal delivery of nadroparin calcium.</gtr:title><gtr:parentPublicationTitle>European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/30e85c1552618e805df26dff11084b6a"><gtr:id>30e85c1552618e805df26dff11084b6a</gtr:id><gtr:otherNames>Gomaa YA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0939-6411</gtr:issn><gtr:outcomeId>544a5e9375a657.43215014</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>43233D48-F3DF-4B45-8D68-C63BCCCD3A42</gtr:id><gtr:title>Microneedle-Mediated Transdermal and Intradermal Drug Delivery</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/96e5749399a4ca900ea8d3471c6158d2"><gtr:id>96e5749399a4ca900ea8d3471c6158d2</gtr:id><gtr:otherNames>Donnelly Ryan F.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:isbn>0470654899</gtr:isbn><gtr:outcomeId>i_37288908923bf19e5c</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A7A366DD-2CC1-4323-A7F1-82CC86D2873F</gtr:id><gtr:title>Hydrogel-Forming Microneedle Arrays for Enhanced Transdermal Drug Delivery.</gtr:title><gtr:parentPublicationTitle>Advanced functional materials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e163238e93b7eff5a965f10b748b7492"><gtr:id>e163238e93b7eff5a965f10b748b7492</gtr:id><gtr:otherNames>Donnelly RF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1616-301X</gtr:issn><gtr:outcomeId>doi_53cfbffbf854c70f</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C4E9DF20-57C0-4CAF-A1D7-1BB83EA73F0B</gtr:id><gtr:title>Microneedle-mediated intradermal nanoparticle delivery: Potential for enhanced local administration of hydrophobic pre-formed photosensitisers.</gtr:title><gtr:parentPublicationTitle>Photodiagnosis and photodynamic therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e163238e93b7eff5a965f10b748b7492"><gtr:id>e163238e93b7eff5a965f10b748b7492</gtr:id><gtr:otherNames>Donnelly RF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1572-1000</gtr:issn><gtr:outcomeId>doi_55f94a94aca729b9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3965D75C-7FB9-47CB-81D9-21CAA93AB0B0</gtr:id><gtr:title>Microneedle mediated intradermal delivery of adjuvanted recombinant HIV-1 CN54gp140 effectively primes mucosal boost inoculations.</gtr:title><gtr:parentPublicationTitle>Journal of controlled release : official journal of the Controlled Release Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a92039c18197b15c680f6ebad69b4926"><gtr:id>a92039c18197b15c680f6ebad69b4926</gtr:id><gtr:otherNames>Pattani A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0168-3659</gtr:issn><gtr:outcomeId>544a5e931468c0.50946775</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FFE9A003-DBB4-442F-B60C-38CFF328D96B</gtr:id><gtr:title>Microneedle arrays as medical devices for enhanced transdermal drug delivery.</gtr:title><gtr:parentPublicationTitle>Expert review of medical devices</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/77a908b607119e89548057df19eb3ddc"><gtr:id>77a908b607119e89548057df19eb3ddc</gtr:id><gtr:otherNames>Garland MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1743-4440</gtr:issn><gtr:outcomeId>544a5e94810dd8.28469228</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3329EF54-AF4F-49DE-91C2-3DC46235359E</gtr:id><gtr:title>Hydrogel-forming and dissolving microneedles for enhanced delivery of photosensitizers and precursors.</gtr:title><gtr:parentPublicationTitle>Photochemistry and photobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e163238e93b7eff5a965f10b748b7492"><gtr:id>e163238e93b7eff5a965f10b748b7492</gtr:id><gtr:otherNames>Donnelly RF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0031-8655</gtr:issn><gtr:outcomeId>doi_55f94a94acc366a3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>433220F8-19E0-42B8-A28C-2FB2E6440ECC</gtr:id><gtr:title>Influence of a pore-forming agent on swelling, network parameters, and permeability of poly(ethylene glycol)-crosslinked poly(methyl vinyl ether-co-maleic acid) hydrogels: Application in transdermal delivery systems</gtr:title><gtr:parentPublicationTitle>Journal of Applied Polymer Science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bd6d26a80951c08687604df42fbd5f22"><gtr:id>bd6d26a80951c08687604df42fbd5f22</gtr:id><gtr:otherNames>Raj Singh T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-8995</gtr:issn><gtr:outcomeId>5a35f3fc76a3b9.09378357</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9B836F82-74D6-43CF-9944-7995E6F6951A</gtr:id><gtr:title>Microneedle arrays allow lower microbial penetration than hypodermic needles in vitro.</gtr:title><gtr:parentPublicationTitle>Pharmaceutical research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e163238e93b7eff5a965f10b748b7492"><gtr:id>e163238e93b7eff5a965f10b748b7492</gtr:id><gtr:otherNames>Donnelly RF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0724-8741</gtr:issn><gtr:outcomeId>544a5e966cac36.78835452</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6379B1E6-94BD-43C3-B80B-2120EB0F2F66</gtr:id><gtr:title>Microneedle pre-treatment of human skin improves 5-aminolevulininc acid (ALA)- and 5-aminolevulinic acid methyl ester (MAL)-induced PpIX production for topical photodynamic therapy without increase in pain or erythema.</gtr:title><gtr:parentPublicationTitle>Pharmaceutical research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a876fe780d09ab2f2a73dddd5fd17cc"><gtr:id>2a876fe780d09ab2f2a73dddd5fd17cc</gtr:id><gtr:otherNames>Mikolajewska P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0724-8741</gtr:issn><gtr:outcomeId>doi_55f94a94ac754300</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>871178A9-590C-4F02-8C3E-CB123C0DF528</gtr:id><gtr:title>Microneedle-mediated transdermal bacteriophage delivery.</gtr:title><gtr:parentPublicationTitle>European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0cdb4e64a934afd37266159c0470fcb5"><gtr:id>0cdb4e64a934afd37266159c0470fcb5</gtr:id><gtr:otherNames>Ryan E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0928-0987</gtr:issn><gtr:outcomeId>544a5e93ad8905.78703518</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EB944BF7-486F-4790-A369-4A26FC912221</gtr:id><gtr:title>Flux of ionic dyes across microneedle-treated skin: effect of molecular characteristics.</gtr:title><gtr:parentPublicationTitle>International journal of pharmaceutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/30e85c1552618e805df26dff11084b6a"><gtr:id>30e85c1552618e805df26dff11084b6a</gtr:id><gtr:otherNames>Gomaa YA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0378-5173</gtr:issn><gtr:outcomeId>544a5e93494209.03290611</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>71072E44-31F7-4230-B431-09335F19022A</gtr:id><gtr:title>Optical coherence tomography is a valuable tool in the study of the effects of microneedle geometry on skin penetration characteristics and in-skin dissolution.</gtr:title><gtr:parentPublicationTitle>Journal of controlled release : official journal of the Controlled Release Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e163238e93b7eff5a965f10b748b7492"><gtr:id>e163238e93b7eff5a965f10b748b7492</gtr:id><gtr:otherNames>Donnelly RF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0168-3659</gtr:issn><gtr:outcomeId>doi_55f94a94ac93687a</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DE4A3D28-BA81-4F1E-9289-2ECA5670937B</gtr:id><gtr:title>Laser-engineered dissolving microneedle arrays for protein delivery: potential for enhanced intradermal vaccination.</gtr:title><gtr:parentPublicationTitle>The Journal of pharmacy and pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a5b7048b696adf8904e091eaf21f562b"><gtr:id>a5b7048b696adf8904e091eaf21f562b</gtr:id><gtr:otherNames>McCrudden MT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-3573</gtr:issn><gtr:outcomeId>544a5e91065cc3.88756427</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>355DDDCF-1527-4C0A-AC78-0479EAFC22A9</gtr:id><gtr:title>Microporation techniques for enhanced delivery of therapeutic agents.</gtr:title><gtr:parentPublicationTitle>Recent patents on drug delivery &amp; formulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba13692032da6f161afaeed241d6571d"><gtr:id>ba13692032da6f161afaeed241d6571d</gtr:id><gtr:otherNames>Singh TR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1872-2113</gtr:issn><gtr:outcomeId>544a5e962e67c3.57463039</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0988FC26-2074-44E0-85FA-75ABD1AC2AC8</gtr:id><gtr:title>Microneedle-based drug delivery systems: microfabrication, drug delivery, and safety.</gtr:title><gtr:parentPublicationTitle>Drug delivery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e163238e93b7eff5a965f10b748b7492"><gtr:id>e163238e93b7eff5a965f10b748b7492</gtr:id><gtr:otherNames>Donnelly RF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1071-7544</gtr:issn><gtr:outcomeId>544a5e95ea7bb5.70079941</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>74AEAF41-841C-4345-96E9-C262C781FE51</gtr:id><gtr:title>Microneedles for intradermal and transdermal drug delivery.</gtr:title><gtr:parentPublicationTitle>European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f603281aae4767d6946f6df1e9b9577"><gtr:id>4f603281aae4767d6946f6df1e9b9577</gtr:id><gtr:otherNames>Tuan-Mahmood TM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0928-0987</gtr:issn><gtr:outcomeId>544a5e91df7f92.58693696</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D7664C33-8947-42B0-9C5F-C2B4565BDAF4</gtr:id><gtr:title>Influence of skin model on in vitro performance of drug-loaded soluble microneedle arrays.</gtr:title><gtr:parentPublicationTitle>International journal of pharmaceutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/77a908b607119e89548057df19eb3ddc"><gtr:id>77a908b607119e89548057df19eb3ddc</gtr:id><gtr:otherNames>Garland MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0378-5173</gtr:issn><gtr:outcomeId>doi_55f94a94ac892448</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>73098FF5-8559-4729-9851-CB63C42C5CCA</gtr:id><gtr:title>Review of patents on microneedle applicators.</gtr:title><gtr:parentPublicationTitle>Recent patents on drug delivery &amp; formulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba13692032da6f161afaeed241d6571d"><gtr:id>ba13692032da6f161afaeed241d6571d</gtr:id><gtr:otherNames>Singh TR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1872-2113</gtr:issn><gtr:outcomeId>544a5e94e38524.75413663</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D9778F50-8F66-4C8D-8FC1-D9CC43DEE9A2</gtr:id><gtr:title>Skin dendritic cell targeting via microneedle arrays laden with antigen-encapsulated poly-D,L-lactide-co-glycolide nanoparticles induces efficient antitumor and antiviral immune responses.</gtr:title><gtr:parentPublicationTitle>ACS nano</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/34d87664fbdf0fd281e1bd6046c4a3d0"><gtr:id>34d87664fbdf0fd281e1bd6046c4a3d0</gtr:id><gtr:otherNames>Zaric M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1936-0851</gtr:issn><gtr:outcomeId>544a5e927c0c55.48560605</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3F21A56C-1402-40E2-A0C2-09A40AC37626</gtr:id><gtr:title>Design, optimization and characterisation of polymeric microneedle arrays prepared by a novel laser-based micromoulding technique.</gtr:title><gtr:parentPublicationTitle>Pharmaceutical research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e163238e93b7eff5a965f10b748b7492"><gtr:id>e163238e93b7eff5a965f10b748b7492</gtr:id><gtr:otherNames>Donnelly RF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0724-8741</gtr:issn><gtr:outcomeId>doi_55f94a94ac6b11a1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9B6520B0-F89C-451F-90BB-08A4D009F631</gtr:id><gtr:title>Microneedle/nanoencapsulation-mediated transdermal delivery: mechanistic insights.</gtr:title><gtr:parentPublicationTitle>European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/30e85c1552618e805df26dff11084b6a"><gtr:id>30e85c1552618e805df26dff11084b6a</gtr:id><gtr:otherNames>Gomaa YA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0939-6411</gtr:issn><gtr:outcomeId>544a5e924bb0a7.97813801</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F0B2A167-29DE-4549-9B9F-DE7165D64804</gtr:id><gtr:title>Effects of microneedle length, density, insertion time and multiple applications on human skin barrier function: assessments by transepidermal water loss.</gtr:title><gtr:parentPublicationTitle>Toxicology in vitro : an international journal published in association with BIBRA</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/30e85c1552618e805df26dff11084b6a"><gtr:id>30e85c1552618e805df26dff11084b6a</gtr:id><gtr:otherNames>Gomaa YA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0887-2333</gtr:issn><gtr:outcomeId>544a5e9552d2e1.67607942</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E7651678-9D70-45D7-BA76-0F1E22A47BF6</gtr:id><gtr:title>Processing difficulties and instability of carbohydrate microneedle arrays.</gtr:title><gtr:parentPublicationTitle>Drug development and industrial pharmacy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e163238e93b7eff5a965f10b748b7492"><gtr:id>e163238e93b7eff5a965f10b748b7492</gtr:id><gtr:otherNames>Donnelly RF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0363-9045</gtr:issn><gtr:outcomeId>544a5e969c4a19.80608253</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D19A9A4-778D-46FB-9352-E2B4FE8B120F</gtr:id><gtr:title>Investigation of solute permeation across hydrogels composed of poly(methyl vinyl ether-
 
 -maleic acid) and poly(ethylene glycol)</gtr:title><gtr:parentPublicationTitle>Journal of Pharmacy and Pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bd6d26a80951c08687604df42fbd5f22"><gtr:id>bd6d26a80951c08687604df42fbd5f22</gtr:id><gtr:otherNames>Raj Singh T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>doi_55f94a94accba6d9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CDE8BAA4-B45D-4774-A400-92CFDF861F0D</gtr:id><gtr:title>Laser-engineered dissolving microneedle arrays for transdermal macromolecular drug delivery.</gtr:title><gtr:parentPublicationTitle>Pharmaceutical research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa6e25087d8b4246a1bf520f7ef17874"><gtr:id>aa6e25087d8b4246a1bf520f7ef17874</gtr:id><gtr:otherNames>Migalska K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0724-8741</gtr:issn><gtr:outcomeId>doi_55f94a94ac7eb1de</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D65810C3-B144-458A-9441-7637C512BAE0</gtr:id><gtr:title>Hydrogel-forming microneedle arrays exhibit antimicrobial properties: potential for enhanced patient safety.</gtr:title><gtr:parentPublicationTitle>International journal of pharmaceutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e163238e93b7eff5a965f10b748b7492"><gtr:id>e163238e93b7eff5a965f10b748b7492</gtr:id><gtr:otherNames>Donnelly RF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0378-5173</gtr:issn><gtr:outcomeId>544a5e921d5473.50459684</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AB2D968F-BDC5-47A2-93BF-3FFBA708FE38</gtr:id><gtr:title>Microneedle-mediated vaccine delivery: harnessing cutaneous immunobiology to improve efficacy.</gtr:title><gtr:parentPublicationTitle>Expert opinion on drug delivery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a8c9880e39cb5dcc843bbe50ce044ec8"><gtr:id>a8c9880e39cb5dcc843bbe50ce044ec8</gtr:id><gtr:otherNames>Al-Zahrani S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1742-5247</gtr:issn><gtr:outcomeId>544a5e941cf982.56796744</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5E21A2F7-8B11-4BFB-9468-9A88DCC5CB15</gtr:id><gtr:title>Hydrogel-forming microneedles prepared from &amp;quot;super swelling&amp;quot; polymers combined with lyophilised wafers for transdermal drug delivery.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e163238e93b7eff5a965f10b748b7492"><gtr:id>e163238e93b7eff5a965f10b748b7492</gtr:id><gtr:otherNames>Donnelly RF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5675dc868cd94</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>969CEE07-CB19-4CD4-A7AB-C2B24614ED5C</gtr:id><gtr:title>Dissolving microneedle delivery of nanoparticle-encapsulated antigen elicits efficient cross-priming and Th1 immune responses by murine Langerhans cells.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/34d87664fbdf0fd281e1bd6046c4a3d0"><gtr:id>34d87664fbdf0fd281e1bd6046c4a3d0</gtr:id><gtr:otherNames>Zaric M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>doi_55f94a94acb16da8</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/E020534/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>